ACTUATE THERAPEUTICS
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3β. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ong... oing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.
ACTUATE THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2015-01-01
Address:
Fort Worth, Texas, United States
Country:
United States
Website Url:
http://www.actuatetherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(847) 986-4190
Total Funding:
65.02 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Google Maps Content Delivery Network Global Site Tag
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
ExpressCells
ExpressCells creates custom cell lines for biological research and drug discovery.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
LucasPye BIO
A Contract Development and Manufacturing Organization (CDMO) that manufactures protein-therapeutic and viral-therapeutic drug products.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Current Advisors List
Board_member
Board_member
2015-01-01
Current Employees Featured
Andrew Mazar Co-founder @ Actuate Therapeutics
Co-founder
Daniel Schmitt President & Chief Executive Officer @ Actuate Therapeutics
President & Chief Executive Officer
Francis Giles Chief Medical Officer @ Actuate Therapeutics
Chief Medical Officer
Founder
Investors List
DEFTA Partners
DEFTA Partners investment in Series B - Actuate Therapeutics
Kairos Ventures
Kairos Ventures investment in Series B - Actuate Therapeutics
Bios Partners
Bios Partners investment in Series B - Actuate Therapeutics
Kairos Ventures
Kairos Ventures investment in Series B - Actuate Therapeutics
DEFTA Partners
DEFTA Partners investment in Series B - Actuate Therapeutics
Tech Coast Angels
Tech Coast Angels investment in Series B - Actuate Therapeutics
Bios Partners
Bios Partners investment in Series B - Actuate Therapeutics
Tech Coast Angels
Tech Coast Angels investment in Convertible Note - Actuate Therapeutics
Official Site Inspections
http://www.actuatetherapeutics.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.13 K
- Host name: actuate.tempurl.host
- IP address: 207.246.122.8
- Location: Piscataway United States
- Latitude: 40.5511
- Longitude: -74.4606
- Metro Code: 501
- Timezone: America/New_York
- Postal: 08854
More informations about "Actuate Therapeutics"
Actuate Therapeutics - Crunchbase Company Profile
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private …See details»
Actuate Therapeutics, Inc. | LinkedIn
Actuate Therapeutics, Inc. Pharmaceutical Manufacturing Fort Worth, Texas 833 followers Actuate is a clinical-stage biopharma company dedicated to developing therapies for cancers with high unmet ...See details»
Actuate Therapeutics Therapeutics - A Kairos Ventures …
Company Summary. Actuate Therapeutics is developing novel therapeutics that target Glycogen Synthase Kinase-3β (GSK-3β). Activity and overexpression of GSK-3β have been implicated in many conditions, including cancer, …See details»
Actuate Therapeutics - Overview, News & Similar companies
Actuate Therapeutics contact info: Phone number: (817) 887-8455 Website: www.actuatetherapeutics.com What does Actuate Therapeutics do? Actuate is a clinical stage …See details»
Actuate Therapeutics (ACTU) Company Profile
Aug 13, 2024 Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen …See details»
Actuate Therapeutics (USA) Funding: $65M
Apr 24, 2025 Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work …See details»
Actuate Therapeutics, Inc. Company Profile | Fort Worth, TX ...
Find company research, competitor information, contact details & financial data for Actuate Therapeutics, Inc. of Fort Worth, TX. Get the latest business insights from Dun & Bradstreet.See details»
Actuate Therapeutics, Inc. Common stock (ACTU) - Yahoo Finance
See the company profile for Actuate Therapeutics, Inc. Common stock (ACTU) including business summary, industry/sector information, number of employees, business summary, corporate …See details»
Improving Clinical Outcomes in Cancer Treatment
Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41).Elraglusib has shown tremendous potential in the treatment of many …See details»
ACTU - Actuate Therapeutics, Inc. | Company Profile | OTC Markets
Mar 7, 2025 actuatetherapeutics.com (817) 887-8455. info@actuatetherapeutics.com. Business Description. Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses …See details»
Actuate Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Its not for the faint of heart, said Jeffrey Finer, CEO of Septerna, a San Francisco area drugmaker that in October raised $288 million from an IPO.Finer, along with the CEOs of two other …See details»
Actuate Therapeutics - Cbonds.com
Actuate Therapeutics. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»
Actuate Therapeutics in the News - University of Illinois Chicago
Jun 17, 2019 Actuate Therapeutics continues Phase 1/2 clinical trials after raising $21.7 Million in a Series B financing. Actuate (formerly Apotheca) Therapeutics, a private biopharmaceutical …See details»
Corporate Overview - actuatetherapeutics.com
4 Elraglusib (injection) Program Preclinical Phase 1 Phase 2 Phase 3 Milestones Pancreatic Cancer (with GnP) 1st line metastatic Adult Actuate-1801 Administrative analysis of interim …See details»
Investor Relations | Actuate Therapeutics
May 7, 2025 Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, …See details»
Actuate Therapeutics Announces Details for 2025 ASCO Annual
2 hours ago A replay of the event will be available on the Investor Relations section of the Actuate website. The Actuate-1801 Part 3B study (NCT03678883) is a randomized, controlled …See details»
Actuate Therapeutics - VentureRadar
Website: https://actuatetherapeutics.com/ Develops novel therapeutics targeting Glycogen Synthase Kinase-3ß (GSK-3ß) for treatment of cancer, Alzheimer's, bipolar ...See details»
Actuate Therapeutics Announces Details for 2025 ASCO Annual …
2 hours ago Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal …See details»
News and Media | Actuate Therapeutics Investors
May 7, 2025 Cookie Duration Description; cookielawinfo-checkbox-analytics: 11 months: This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent …See details»
Actuate Therapeutics Announces Details for 2025 ASCO Annual …
2 hours ago Oral Presentation Date and Time: Saturday, May 31, 2025, 4:48 PM CDT. Abstract Title: Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma …See details»